Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention.
Adenocarcinoma of the prostate remains a significant public health problem and a prevalent cancer in men. Prostate-specific antigen used as a biomarker has established a clear migration of patients towards earlier-stage disease at presentation. However, in spite of process improvements in traditional therapies including surgery, radiation therapy, and hormone management, there remains a significant cohort of patients with intermediate- to high-risk features for poor outcome in spite of optimal use of traditional management. This paper focuses on future treatment strategies integrating new therapeutic options with traditional management, specifically to pinpoint new radiation therapy strategies.
Fitzgerald
T J
TJ
Department of Radiation Oncology, University of Massachusetts Medical School, 55 Lake Avenue North Worcester, MA 01605, USA. fitzgert@ummhc.org
Wang
Tao
T
Goel
Hira Lal
HL
Huang
Jiayi
J
Stein
Gary
G
Lian
Jane
J
Davis
Roger J
RJ
Doxsey
Steven
S
Balaji
K C
KC
Aronowitz
Jesse
J
Languino
Lucia R
LR
D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011836:Radiation Tolerance; D012307:Risk Factors; D016896:Treatment Outcome
D017430:Prostate-Specific Antigen